# Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

> **NCT05439629** · PHASE3 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 488 (actual)

## Conditions studied

- Neovascular (Wet) Age-related Macular Degeneration

## Interventions

- **DRUG:** BAT5906 injection
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT05439629
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2025-04-22
- **Final completion:** 2025-04-22
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05439629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05439629, "Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05439629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*